Advertisement
Guest User

Untitled

a guest
Feb 20th, 2019
157
0
Never
Not a member of Pastebin yet? Sign Up, it unlocks many cool features!
text 22.60 KB | None | 0 0
  1. ---------- MESSAGE FOLLOWS ----------
  2. Return-Path: <setup@clearitie.com>
  3. Message-ID: <a7e9c28c91dce1cb6fee9ef106115ded@swift.generated>
  4. Date: Thu, 21 Feb 2019 02:58:24 +0000
  5. Subject: Certification Letter for the Study (20046) Video Training
  6. From: CLEARiTIE Platform <setup@clearitie.com>
  7. To: sara.fernandezmate@bayer.com
  8. MIME-Version: 1.0
  9. Content-Type: text/html; charset=utf-8
  10. Content-Transfer-Encoding: quoted-printable
  11. X-Peer: 127.0.0.1
  12.  
  13. <!DOCTYPE html>
  14. <html lang=3D"en-US">
  15. <head>
  16. <meta charse=
  17. t=3D"utf-8">
  18. </head>
  19. <body>
  20. <!DOCTYPE html>
  21. <html l=
  22. ang=3D"en">
  23. <head>
  24. <title>Your Certification</title>
  25.  
  26. =
  27. <meta charset=3D"UTF-8">
  28.  
  29. </head>
  30.  
  31. <body>
  32. =
  33. =20
  34. <div class=3D"content">
  35. <p>
  36. Sara Fernandez<b=
  37. r>
  38.  
  39. =20
  40. 17 Jan 2019<br>
  41. </p>
  42.  
  43. <p>Dear Sara Fernandez,</p>=
  44.  
  45.  
  46. <p>
  47. We are pleased to inform yo=
  48. u that you successfully completed the following
  49. videos fo=
  50. r the ESRD Study (20046) training:
  51. </p>
  52.  
  53. <ul>=
  54.  
  55. <li>1) PROTOCOL PART 1: BACKGROUND I=
  56. NFORMATION</li>
  57. <li>2) PROTOCOL PART =
  58. 2: STUDY PROTOCOL TRAINING</li>
  59. <li>3=
  60. ) PROTOCOL PART 3: IMPORTANT MEASUREMENTS REPORTING</li>
  61. =
  62. <li>4) STUDY DRUG SCRIPT PART 1</li>
  63. =
  64. <li>5) STUDY DRUG SCRIPT PART 2</li>
  65. =
  66. <li>6) SAFETY TRAINING DEFINITIONS</li>
  67. =
  68. <li>7) SAFETY TRAINING REPORTING</li>
  69. =
  70. <li>8) PRINCIPAL INVESTIGATOR OVERSIGHT</li>
  71. =
  72. <li>9) eCRF</li>
  73. =
  74. <li>10) IxRS</li>
  75. <li>11)=
  76. PKPD</li>
  77. </ul>
  78.  
  79. =20
  80. =
  81. <p>Bayer has been informed about your successful completion.</p>
  82. =
  83.  
  84. <p>Best Regards,</p>
  85. <p>Dr. Martin Prins</p>
  86.  
  87. =
  88. </div>
  89.  
  90. </body>
  91. </html>
  92.  
  93.  
  94. </body>
  95. </html>
  96.  
  97. ------------ END MESSAGE ------------
  98. ---------- MESSAGE FOLLOWS ----------
  99. Return-Path: <setup@clearitie.com>
  100. Message-ID: <a7e9c28c91dce1cb6fee9ef106115ded@swift.generated>
  101. Date: Thu, 21 Feb 2019 02:58:24 +0000
  102. Subject: Certification Letter for the Study (20046) Video Training
  103. From: CLEARiTIE Platform <setup@clearitie.com>
  104. To: sara.fernandezmate@bayer.com
  105. Bcc: setup@clearitie.com
  106. MIME-Version: 1.0
  107. Content-Type: text/html; charset=utf-8
  108. Content-Transfer-Encoding: quoted-printable
  109. X-Peer: 127.0.0.1
  110.  
  111. <!DOCTYPE html>
  112. <html lang=3D"en-US">
  113. <head>
  114. <meta charse=
  115. t=3D"utf-8">
  116. </head>
  117. <body>
  118. <!DOCTYPE html>
  119. <html l=
  120. ang=3D"en">
  121. <head>
  122. <title>Your Certification</title>
  123.  
  124. =
  125. <meta charset=3D"UTF-8">
  126.  
  127. </head>
  128.  
  129. <body>
  130. =
  131. =20
  132. <div class=3D"content">
  133. <p>
  134. Sara Fernandez<b=
  135. r>
  136.  
  137. =20
  138. 17 Jan 2019<br>
  139. </p>
  140.  
  141. <p>Dear Sara Fernandez,</p>=
  142.  
  143.  
  144. <p>
  145. We are pleased to inform yo=
  146. u that you successfully completed the following
  147. videos fo=
  148. r the ESRD Study (20046) training:
  149. </p>
  150.  
  151. <ul>=
  152.  
  153. <li>1) PROTOCOL PART 1: BACKGROUND I=
  154. NFORMATION</li>
  155. <li>2) PROTOCOL PART =
  156. 2: STUDY PROTOCOL TRAINING</li>
  157. <li>3=
  158. ) PROTOCOL PART 3: IMPORTANT MEASUREMENTS REPORTING</li>
  159. =
  160. <li>4) STUDY DRUG SCRIPT PART 1</li>
  161. =
  162. <li>5) STUDY DRUG SCRIPT PART 2</li>
  163. =
  164. <li>6) SAFETY TRAINING DEFINITIONS</li>
  165. =
  166. <li>7) SAFETY TRAINING REPORTING</li>
  167. =
  168. <li>8) PRINCIPAL INVESTIGATOR OVERSIGHT</li>
  169. =
  170. <li>9) eCRF</li>
  171. =
  172. <li>10) IxRS</li>
  173. <li>11)=
  174. PKPD</li>
  175. </ul>
  176.  
  177. =20
  178. =
  179. <p>Bayer has been informed about your successful completion.</p>
  180. =
  181.  
  182. <p>Best Regards,</p>
  183. <p>Dr. Martin Prins</p>
  184.  
  185. =
  186. </div>
  187.  
  188. </body>
  189. </html>
  190.  
  191.  
  192. </body>
  193. </html>
  194.  
  195. ------------ END MESSAGE ------------
  196. ---------- MESSAGE FOLLOWS ----------
  197. Return-Path: <setup@clearitie.com>
  198. Message-ID: <1edba94192af43fc080a8f9370b3e44d@swift.generated>
  199. Date: Thu, 21 Feb 2019 02:58:24 +0000
  200. Subject: Certification Letter for the Study (20046) Video Training
  201. From: CLEARiTIE Platform <setup@clearitie.com>
  202. To: nicole.blakley.ext@bayer.com
  203. MIME-Version: 1.0
  204. Content-Type: text/html; charset=utf-8
  205. Content-Transfer-Encoding: quoted-printable
  206. X-Peer: 127.0.0.1
  207.  
  208. <!DOCTYPE html>
  209. <html lang=3D"en-US">
  210. <head>
  211. <meta charse=
  212. t=3D"utf-8">
  213. </head>
  214. <body>
  215. <!DOCTYPE html>
  216. <html l=
  217. ang=3D"en">
  218. <head>
  219. <title>Your Certification</title>
  220.  
  221. =
  222. <meta charset=3D"UTF-8">
  223.  
  224. </head>
  225.  
  226. <body>
  227. =
  228. =20
  229. <div class=3D"content">
  230. <p>
  231. Nicole Blakley<b=
  232. r>
  233.  
  234. =20
  235. 12 Feb 2019<br>
  236. </p>
  237.  
  238. <p>Dear Nicole Blakley,</p>=
  239.  
  240.  
  241. <p>
  242. We are pleased to inform yo=
  243. u that you successfully completed the following
  244. videos fo=
  245. r the ESRD Study (20046) training:
  246. </p>
  247.  
  248. <ul>=
  249.  
  250. <li>1) PROTOCOL PART 1: BACKGROUND I=
  251. NFORMATION</li>
  252. <li>2) PROTOCOL PART =
  253. 2: STUDY PROTOCOL TRAINING</li>
  254. <li>3=
  255. ) PROTOCOL PART 3: IMPORTANT MEASUREMENTS REPORTING</li>
  256. =
  257. <li>4) STUDY DRUG SCRIPT PART 1</li>
  258. =
  259. <li>5) STUDY DRUG SCRIPT PART 2</li>
  260. =
  261. <li>6) SAFETY TRAINING DEFINITIONS</li>
  262. =
  263. <li>7) SAFETY TRAINING REPORTING</li>
  264. =
  265. <li>8) PRINCIPAL INVESTIGATOR OVERSIGHT</li>
  266. =
  267. <li>9) eCRF</li>
  268. =
  269. <li>10) IxRS</li>
  270. <li>11)=
  271. PKPD</li>
  272. </ul>
  273.  
  274. =20
  275. =
  276. <p>Bayer has been informed about your successful completion.</p>
  277. =
  278.  
  279. <p>Best Regards,</p>
  280. <p>Dr. Martin Prins</p>
  281.  
  282. =
  283. </div>
  284.  
  285. </body>
  286. </html>
  287.  
  288.  
  289. </body>
  290. </html>
  291.  
  292. ------------ END MESSAGE ------------
  293. ---------- MESSAGE FOLLOWS ----------
  294. Return-Path: <setup@clearitie.com>
  295. Message-ID: <1edba94192af43fc080a8f9370b3e44d@swift.generated>
  296. Date: Thu, 21 Feb 2019 02:58:24 +0000
  297. Subject: Certification Letter for the Study (20046) Video Training
  298. From: CLEARiTIE Platform <setup@clearitie.com>
  299. To: nicole.blakley.ext@bayer.com
  300. Bcc: setup@clearitie.com
  301. MIME-Version: 1.0
  302. Content-Type: text/html; charset=utf-8
  303. Content-Transfer-Encoding: quoted-printable
  304. X-Peer: 127.0.0.1
  305.  
  306. <!DOCTYPE html>
  307. <html lang=3D"en-US">
  308. <head>
  309. <meta charse=
  310. t=3D"utf-8">
  311. </head>
  312. <body>
  313. <!DOCTYPE html>
  314. <html l=
  315. ang=3D"en">
  316. <head>
  317. <title>Your Certification</title>
  318.  
  319. =
  320. <meta charset=3D"UTF-8">
  321.  
  322. </head>
  323.  
  324. <body>
  325. =
  326. =20
  327. <div class=3D"content">
  328. <p>
  329. Nicole Blakley<b=
  330. r>
  331.  
  332. =20
  333. 12 Feb 2019<br>
  334. </p>
  335.  
  336. <p>Dear Nicole Blakley,</p>=
  337.  
  338.  
  339. <p>
  340. We are pleased to inform yo=
  341. u that you successfully completed the following
  342. videos fo=
  343. r the ESRD Study (20046) training:
  344. </p>
  345.  
  346. <ul>=
  347.  
  348. <li>1) PROTOCOL PART 1: BACKGROUND I=
  349. NFORMATION</li>
  350. <li>2) PROTOCOL PART =
  351. 2: STUDY PROTOCOL TRAINING</li>
  352. <li>3=
  353. ) PROTOCOL PART 3: IMPORTANT MEASUREMENTS REPORTING</li>
  354. =
  355. <li>4) STUDY DRUG SCRIPT PART 1</li>
  356. =
  357. <li>5) STUDY DRUG SCRIPT PART 2</li>
  358. =
  359. <li>6) SAFETY TRAINING DEFINITIONS</li>
  360. =
  361. <li>7) SAFETY TRAINING REPORTING</li>
  362. =
  363. <li>8) PRINCIPAL INVESTIGATOR OVERSIGHT</li>
  364. =
  365. <li>9) eCRF</li>
  366. =
  367. <li>10) IxRS</li>
  368. <li>11)=
  369. PKPD</li>
  370. </ul>
  371.  
  372. =20
  373. =
  374. <p>Bayer has been informed about your successful completion.</p>
  375. =
  376.  
  377. <p>Best Regards,</p>
  378. <p>Dr. Martin Prins</p>
  379.  
  380. =
  381. </div>
  382.  
  383. </body>
  384. </html>
  385.  
  386.  
  387. </body>
  388. </html>
  389.  
  390. ------------ END MESSAGE ------------
  391. ---------- MESSAGE FOLLOWS ----------
  392. Return-Path: <setup@clearitie.com>
  393. Message-ID: <7e2d6de9ba94da426227b61747e9cf0e@swift.generated>
  394. Date: Thu, 21 Feb 2019 02:58:24 +0000
  395. Subject: Certification Letter for the Study (20046) Video Training
  396. From: CLEARiTIE Platform <setup@clearitie.com>
  397. To: maggie.faries@bayer.com
  398. MIME-Version: 1.0
  399. Content-Type: text/html; charset=utf-8
  400. Content-Transfer-Encoding: quoted-printable
  401. X-Peer: 127.0.0.1
  402.  
  403. <!DOCTYPE html>
  404. <html lang=3D"en-US">
  405. <head>
  406. <meta charse=
  407. t=3D"utf-8">
  408. </head>
  409. <body>
  410. <!DOCTYPE html>
  411. <html l=
  412. ang=3D"en">
  413. <head>
  414. <title>Your Certification</title>
  415.  
  416. =
  417. <meta charset=3D"UTF-8">
  418.  
  419. </head>
  420.  
  421. <body>
  422. =
  423. =20
  424. <div class=3D"content">
  425. <p>
  426. Maggie Faires<br=
  427. >
  428.  
  429. =20
  430. 19 Feb 2019<br>
  431. </p>
  432.  
  433. <p>Dear Maggie Faires,</p>
  434. =
  435.  
  436. <p>
  437. We are pleased to inform you t=
  438. hat you successfully completed the following
  439. videos for t=
  440. he ESRD Study (20046) training:
  441. </p>
  442.  
  443. <ul>
  444. =
  445. <li>1) PROTOCOL PART 1: BACKGROUND INFO=
  446. RMATION</li>
  447. <li>2) PROTOCOL PART 2: =
  448. STUDY PROTOCOL TRAINING</li>
  449. <li>3) P=
  450. ROTOCOL PART 3: IMPORTANT MEASUREMENTS REPORTING</li>
  451. =
  452. <li>4) STUDY DRUG SCRIPT PART 1</li>
  453. =
  454. <li>5) STUDY DRUG SCRIPT PART 2</li>
  455. =
  456. <li>6) SAFETY TRAINING DEFINITIONS</li>
  457. =
  458. <li>7) SAFETY TRAINING REPORTING</li>
  459. =
  460. <li>8) PRINCIPAL INVESTIGATOR OVERSIGHT</li>
  461. =
  462. <li>9) eCRF</li>
  463. =
  464. <li>10) IxRS</li>
  465. <li>11) PK=
  466. PD</li>
  467. </ul>
  468.  
  469. =20
  470. =
  471. <p>Bayer has been informed about your successful completion.</p>
  472.  
  473. =
  474. <p>Best Regards,</p>
  475. <p>Dr. Martin Prins</p>
  476.  
  477. </d=
  478. iv>
  479.  
  480. </body>
  481. </html>
  482.  
  483.  
  484. </body>
  485. </html>
  486.  
  487. ------------ END MESSAGE ------------
  488. ---------- MESSAGE FOLLOWS ----------
  489. Return-Path: <setup@clearitie.com>
  490. Message-ID: <7e2d6de9ba94da426227b61747e9cf0e@swift.generated>
  491. Date: Thu, 21 Feb 2019 02:58:24 +0000
  492. Subject: Certification Letter for the Study (20046) Video Training
  493. From: CLEARiTIE Platform <setup@clearitie.com>
  494. To: maggie.faries@bayer.com
  495. Bcc: setup@clearitie.com
  496. MIME-Version: 1.0
  497. Content-Type: text/html; charset=utf-8
  498. Content-Transfer-Encoding: quoted-printable
  499. X-Peer: 127.0.0.1
  500.  
  501. <!DOCTYPE html>
  502. <html lang=3D"en-US">
  503. <head>
  504. <meta charse=
  505. t=3D"utf-8">
  506. </head>
  507. <body>
  508. <!DOCTYPE html>
  509. <html l=
  510. ang=3D"en">
  511. <head>
  512. <title>Your Certification</title>
  513.  
  514. =
  515. <meta charset=3D"UTF-8">
  516.  
  517. </head>
  518.  
  519. <body>
  520. =
  521. =20
  522. <div class=3D"content">
  523. <p>
  524. Maggie Faires<br=
  525. >
  526.  
  527. =20
  528. 19 Feb 2019<br>
  529. </p>
  530.  
  531. <p>Dear Maggie Faires,</p>
  532. =
  533.  
  534. <p>
  535. We are pleased to inform you t=
  536. hat you successfully completed the following
  537. videos for t=
  538. he ESRD Study (20046) training:
  539. </p>
  540.  
  541. <ul>
  542. =
  543. <li>1) PROTOCOL PART 1: BACKGROUND INFO=
  544. RMATION</li>
  545. <li>2) PROTOCOL PART 2: =
  546. STUDY PROTOCOL TRAINING</li>
  547. <li>3) P=
  548. ROTOCOL PART 3: IMPORTANT MEASUREMENTS REPORTING</li>
  549. =
  550. <li>4) STUDY DRUG SCRIPT PART 1</li>
  551. =
  552. <li>5) STUDY DRUG SCRIPT PART 2</li>
  553. =
  554. <li>6) SAFETY TRAINING DEFINITIONS</li>
  555. =
  556. <li>7) SAFETY TRAINING REPORTING</li>
  557. =
  558. <li>8) PRINCIPAL INVESTIGATOR OVERSIGHT</li>
  559. =
  560. <li>9) eCRF</li>
  561. =
  562. <li>10) IxRS</li>
  563. <li>11) PK=
  564. PD</li>
  565. </ul>
  566.  
  567. =20
  568. =
  569. <p>Bayer has been informed about your successful completion.</p>
  570.  
  571. =
  572. <p>Best Regards,</p>
  573. <p>Dr. Martin Prins</p>
  574.  
  575. </d=
  576. iv>
  577.  
  578. </body>
  579. </html>
  580.  
  581.  
  582. </body>
  583. </html>
  584.  
  585. ------------ END MESSAGE ------------
  586. ---------- MESSAGE FOLLOWS ----------
  587. Return-Path: <setup@clearitie.com>
  588. Message-ID: <e66125abeed2caec75a6d831005958dc@swift.generated>
  589. Date: Thu, 21 Feb 2019 02:58:24 +0000
  590. Subject: Certification Letter for the Study (20046) Video Training
  591. From: CLEARiTIE Platform <setup@clearitie.com>
  592. To: christopher.caira@bayer.com
  593. MIME-Version: 1.0
  594. Content-Type: text/html; charset=utf-8
  595. Content-Transfer-Encoding: quoted-printable
  596. X-Peer: 127.0.0.1
  597.  
  598. <!DOCTYPE html>
  599. <html lang=3D"en-US">
  600. <head>
  601. <meta charse=
  602. t=3D"utf-8">
  603. </head>
  604. <body>
  605. <!DOCTYPE html>
  606. <html l=
  607. ang=3D"en">
  608. <head>
  609. <title>Your Certification</title>
  610.  
  611. =
  612. <meta charset=3D"UTF-8">
  613.  
  614. </head>
  615.  
  616. <body>
  617. =
  618. =20
  619. <div class=3D"content">
  620. <p>
  621. Christopher Cair=
  622. a<br>
  623.  
  624. =20
  625. 17 Jan 2019<br>
  626. </p>
  627.  
  628. <p>Dear Christopher Caira=
  629. ,</p>
  630.  
  631. <p>
  632. We are pleased to info=
  633. rm you that you successfully completed the following
  634. vide=
  635. os for the ESRD Study (20046) training:
  636. </p>
  637.  
  638. =
  639. <ul>
  640. <li>1) PROTOCOL PART 1: BACKGRO=
  641. UND INFORMATION</li>
  642. <li>2) PROTOCOL =
  643. PART 2: STUDY PROTOCOL TRAINING</li>
  644. =
  645. <li>3) PROTOCOL PART 3: IMPORTANT MEASUREMENTS REPORTING</li>
  646. =
  647. <li>4) STUDY DRUG SCRIPT PART 1</li>
  648. =
  649. <li>5) STUDY DRUG SCRIPT PART 2</li>
  650. =
  651. <li>6) SAFETY TRAINING DEFINITIONS</li>
  652. =
  653. <li>7) SAFETY TRAINING REPORTING</li>
  654. =
  655. <li>8) PRINCIPAL INVESTIGATOR OVERSIGHT</li>=
  656.  
  657. <li>9) eCRF</li>
  658. =
  659. <li>10) IxRS</li>
  660. =
  661. <li>11) PKPD</li>
  662. </ul>
  663.  
  664. =
  665. =20
  666. <p>Bayer has been informed about your successful completion.=
  667. </p>
  668.  
  669. <p>Best Regards,</p>
  670. <p>Dr. Martin Prins</p>
  671.  
  672. =
  673. </div>
  674.  
  675. </body>
  676. </html>
  677.  
  678.  
  679. </body>
  680. </html>
  681.  
  682. ------------ END MESSAGE ------------
  683. ---------- MESSAGE FOLLOWS ----------
  684. Return-Path: <setup@clearitie.com>
  685. Message-ID: <e66125abeed2caec75a6d831005958dc@swift.generated>
  686. Date: Thu, 21 Feb 2019 02:58:24 +0000
  687. Subject: Certification Letter for the Study (20046) Video Training
  688. From: CLEARiTIE Platform <setup@clearitie.com>
  689. To: christopher.caira@bayer.com
  690. Bcc: setup@clearitie.com
  691. MIME-Version: 1.0
  692. Content-Type: text/html; charset=utf-8
  693. Content-Transfer-Encoding: quoted-printable
  694. X-Peer: 127.0.0.1
  695.  
  696. <!DOCTYPE html>
  697. <html lang=3D"en-US">
  698. <head>
  699. <meta charse=
  700. t=3D"utf-8">
  701. </head>
  702. <body>
  703. <!DOCTYPE html>
  704. <html l=
  705. ang=3D"en">
  706. <head>
  707. <title>Your Certification</title>
  708.  
  709. =
  710. <meta charset=3D"UTF-8">
  711.  
  712. </head>
  713.  
  714. <body>
  715. =
  716. =20
  717. <div class=3D"content">
  718. <p>
  719. Christopher Cair=
  720. a<br>
  721.  
  722. =20
  723. 17 Jan 2019<br>
  724. </p>
  725.  
  726. <p>Dear Christopher Caira=
  727. ,</p>
  728.  
  729. <p>
  730. We are pleased to info=
  731. rm you that you successfully completed the following
  732. vide=
  733. os for the ESRD Study (20046) training:
  734. </p>
  735.  
  736. =
  737. <ul>
  738. <li>1) PROTOCOL PART 1: BACKGRO=
  739. UND INFORMATION</li>
  740. <li>2) PROTOCOL =
  741. PART 2: STUDY PROTOCOL TRAINING</li>
  742. =
  743. <li>3) PROTOCOL PART 3: IMPORTANT MEASUREMENTS REPORTING</li>
  744. =
  745. <li>4) STUDY DRUG SCRIPT PART 1</li>
  746. =
  747. <li>5) STUDY DRUG SCRIPT PART 2</li>
  748. =
  749. <li>6) SAFETY TRAINING DEFINITIONS</li>
  750. =
  751. <li>7) SAFETY TRAINING REPORTING</li>
  752. =
  753. <li>8) PRINCIPAL INVESTIGATOR OVERSIGHT</li>=
  754.  
  755. <li>9) eCRF</li>
  756. =
  757. <li>10) IxRS</li>
  758. =
  759. <li>11) PKPD</li>
  760. </ul>
  761.  
  762. =
  763. =20
  764. <p>Bayer has been informed about your successful completion.=
  765. </p>
  766.  
  767. <p>Best Regards,</p>
  768. <p>Dr. Martin Prins</p>
  769.  
  770. =
  771. </div>
  772.  
  773. </body>
  774. </html>
  775.  
  776.  
  777. </body>
  778. </html>
  779.  
  780. ------------ END MESSAGE ------------
  781. ---------- MESSAGE FOLLOWS ----------
  782. Return-Path: <setup@clearitie.com>
  783. Message-ID: <3febe0b9aab82ee4a17f248af2b947b4@swift.generated>
  784. Date: Thu, 21 Feb 2019 02:58:24 +0000
  785. Subject: Certification Letter for the Study (20046) Video Training
  786. From: CLEARiTIE Platform <setup@clearitie.com>
  787. To: esther.munozpuig@bayer.com
  788. MIME-Version: 1.0
  789. Content-Type: text/html; charset=utf-8
  790. Content-Transfer-Encoding: quoted-printable
  791. X-Peer: 127.0.0.1
  792.  
  793. <!DOCTYPE html>
  794. <html lang=3D"en-US">
  795. <head>
  796. <meta charse=
  797. t=3D"utf-8">
  798. </head>
  799. <body>
  800. <!DOCTYPE html>
  801. <html l=
  802. ang=3D"en">
  803. <head>
  804. <title>Your Certification</title>
  805.  
  806. =
  807. <meta charset=3D"UTF-8">
  808.  
  809. </head>
  810.  
  811. <body>
  812. =
  813. =20
  814. <div class=3D"content">
  815. <p>
  816. Esther Mu=C3=
  817. =B1oz<br>
  818.  
  819. =20
  820. 01 Feb 2019<br>
  821. </p>
  822.  
  823. <p>Dear Esther Mu=
  824. =C3=B1oz,</p>
  825.  
  826. <p>
  827. We are pleased=
  828. to inform you that you successfully completed the following
  829. =
  830. videos for the ESRD Study (20046) training:
  831. </p>
  832.  
  833. =
  834. <ul>
  835. <li>1) PROTOCOL PART 1:=
  836. BACKGROUND INFORMATION</li>
  837. <li>2) P=
  838. ROTOCOL PART 2: STUDY PROTOCOL TRAINING</li>
  839. =
  840. <li>3) PROTOCOL PART 3: IMPORTANT MEASUREMENTS REPORTING</li>
  841. =
  842. <li>4) STUDY DRUG SCRIPT PART 1</li>
  843. =
  844. <li>5) STUDY DRUG SCRIPT PART 2</li>
  845. =
  846. <li>6) SAFETY TRAINING DEFINITIONS</li>
  847. =
  848. <li>7) SAFETY TRAINING REPORTING</li>=
  849.  
  850. <li>8) PRINCIPAL INVESTIGATOR OVERSI=
  851. GHT</li>
  852. <li>9) eCRF</li>
  853. =
  854. <li>10) IxRS</li>
  855. =
  856. <li>11) PKPD</li>
  857. </ul>
  858.  
  859. =
  860. =20
  861. <p>Bayer has been informed about your successful com=
  862. pletion.</p>
  863.  
  864. <p>Best Regards,</p>
  865. <p>Dr. Martin Prins</p>
  866. =
  867.  
  868. </div>
  869.  
  870. </body>
  871. </html>
  872.  
  873.  
  874. </body>
  875. </ht=
  876. ml>
  877.  
  878. ------------ END MESSAGE ------------
  879. ---------- MESSAGE FOLLOWS ----------
  880. Return-Path: <setup@clearitie.com>
  881. Message-ID: <3febe0b9aab82ee4a17f248af2b947b4@swift.generated>
  882. Date: Thu, 21 Feb 2019 02:58:24 +0000
  883. Subject: Certification Letter for the Study (20046) Video Training
  884. From: CLEARiTIE Platform <setup@clearitie.com>
  885. To: esther.munozpuig@bayer.com
  886. Bcc: setup@clearitie.com
  887. MIME-Version: 1.0
  888. Content-Type: text/html; charset=utf-8
  889. Content-Transfer-Encoding: quoted-printable
  890. X-Peer: 127.0.0.1
  891.  
  892. <!DOCTYPE html>
  893. <html lang=3D"en-US">
  894. <head>
  895. <meta charse=
  896. t=3D"utf-8">
  897. </head>
  898. <body>
  899. <!DOCTYPE html>
  900. <html l=
  901. ang=3D"en">
  902. <head>
  903. <title>Your Certification</title>
  904.  
  905. =
  906. <meta charset=3D"UTF-8">
  907.  
  908. </head>
  909.  
  910. <body>
  911. =
  912. =20
  913. <div class=3D"content">
  914. <p>
  915. Esther Mu=C3=
  916. =B1oz<br>
  917.  
  918. =20
  919. 01 Feb 2019<br>
  920. </p>
  921.  
  922. <p>Dear Esther Mu=
  923. =C3=B1oz,</p>
  924.  
  925. <p>
  926. We are pleased=
  927. to inform you that you successfully completed the following
  928. =
  929. videos for the ESRD Study (20046) training:
  930. </p>
  931.  
  932. =
  933. <ul>
  934. <li>1) PROTOCOL PART 1:=
  935. BACKGROUND INFORMATION</li>
  936. <li>2) P=
  937. ROTOCOL PART 2: STUDY PROTOCOL TRAINING</li>
  938. =
  939. <li>3) PROTOCOL PART 3: IMPORTANT MEASUREMENTS REPORTING</li>
  940. =
  941. <li>4) STUDY DRUG SCRIPT PART 1</li>
  942. =
  943. <li>5) STUDY DRUG SCRIPT PART 2</li>
  944. =
  945. <li>6) SAFETY TRAINING DEFINITIONS</li>
  946. =
  947. <li>7) SAFETY TRAINING REPORTING</li>=
  948.  
  949. <li>8) PRINCIPAL INVESTIGATOR OVERSI=
  950. GHT</li>
  951. <li>9) eCRF</li>
  952. =
  953. <li>10) IxRS</li>
  954. =
  955. <li>11) PKPD</li>
  956. </ul>
  957.  
  958. =
  959. =20
  960. <p>Bayer has been informed about your successful com=
  961. pletion.</p>
  962.  
  963. <p>Best Regards,</p>
  964. <p>Dr. Martin Prins</p>
  965. =
  966.  
  967. </div>
  968.  
  969. </body>
  970. </html>
  971.  
  972.  
  973. </body>
  974. </ht=
  975. ml>
  976.  
  977. ------------ END MESSAGE ------------
Advertisement
Add Comment
Please, Sign In to add comment
Advertisement